Owlstone Medical, the innovative company which promises to revolutionise the diagnosis of cancer by simply analysing a patient's breath has been given a major funding boost.
One of the UK’s most promising medtech start-ups, Owlstone Medical has been given a major boost by GSK’s decision to include its technology in a major clinical trial programme.
The venture capital arm of the UK’s biggest insurance firm Aviva is to invest $5 million (£4m) in Owlstone Medical, one of the country’s most promising and potentially groundbreaking diagno
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.